Ginkgo Bioworks Bets on Autonomous Labs Amid Headwinds
Ginkgo Bioworks Holdings, Inc. ((DNA)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ginkgo Bioworks’ latest earnings call struck a cautiously optimistic tone as management highlighted major advances in its autonomous lab strategy alongside tighter financial discipline. Executives emphasized that while revenue and profitability pressures remain, the company is leaning into an investment-led growth model built around AI-driven biology and sharply reduced cash burn.
Autonomous Lab Breakthrough with OpenAI
Ginkgo showcased a flagship collaboration with OpenAI that linked GPT‑5 as an “AI scientist” to its autonomous lab. On a cell‑free protein synthesis challenge, the system delivered a 40% performance gain over the state of the art in just six experimental rounds, underscoring a differentiated, AI‑in‑the‑loop lab platform.
Federal Contract Underscores Demand
The company signed a $47 million agreement with Pacific Northwest National Labs to build a 97‑RAC autonomous facility, a major validation from a federal research customer. Ginkgo has already installed the first 18 robots in the Genesis project, signaling early deployment momentum for its RAC‑based infrastructure.
Nebula Scale-Up Draws Market Attention
In Boston, the Nebula site has grown into an autonomous lab with more than 50 RACs and served as a showcase during SLAS tours, hosting 590 visitors. Management plans to double Nebula’s capacity to about 100 RACs by the first half, using the site to persuade pharma, national labs and universities of its scalable model.
Cash Burn Falls Sharply with 2026 Target
Full‑year cash burn dropped 55%, from $383 million in 2024 to $171 million in 2025, with Q4 burn improving 15% year over year to $47 million. The company reframed guidance around runway rather than revenue, aiming to cut 2026 cash burn further to a range of $125 million to $150 million.
Deep Cuts in R&D and G&A Spending
Restructuring slashed Cell Engineering R&D costs by 42% to $159 million in 2025, with Q4 R&D down 44% to $28 million. General and administrative expenses in Cell Engineering were cut even more, falling 51% for the year to $56 million and 40% in Q4 to $12 million, marking a leaner operating structure.
Losses Narrow but Profit Still Distant
Operating performance improved as Cell Engineering’s full‑year operating loss shrank to $96 million from $219 million and Q4 losses narrowed to $17 million from $38 million. Adjusted EBITDA remained negative but improved to ‑$36 million in Q4 and ‑$167 million for 2025, compared with ‑$57 million and ‑$293 million a year earlier.
Biosecurity Divestiture to Refocus Capital
Management announced plans to divest its Biosecurity business so it can concentrate capital on autonomous labs and related platforms. Ginkgo intends to keep a minority stake, betting that external investors will scale the biosecurity opportunity while freeing its own balance sheet for core initiatives.
Growing Data and Services Footprint
The Datapoints data‑generation business has ramped quickly since launch, now working with around ten top pharmaceutical companies and releasing public datasets to fuel bio‑AI. Ginkgo has completed about 250 Solutions partnerships over the last decade and is broadening its cloud‑lab and datapoints offerings to drive recurring revenue.
Cell Engineering Revenue Under Pressure
Despite strategic wins, Cell Engineering revenue fell to $26 million in Q4 2025, down 26% year over year, with full‑year revenue slipping to $133 million from $174 million. Excluding noncash deferred items, revenue was roughly flat at $125 million versus $129 million, while supported revenue‑generating programs declined 4% to 109 amid continuing program rationalization.
Persistent GAAP Losses and EBITDA Deficit
The company still reports GAAP net losses, driven by noncash and nonrecurring items detailed in its financial statements. Even with better trends, adjusted EBITDA has yet to turn positive, reminding investors that profitability remains a medium‑term goal rather than an immediate outcome.
Excess Real Estate Weighs on Results
Excess lease space remains a drag, carrying $54 million of costs in 2025, including $15 million in the fourth quarter, without generating corresponding revenue. Management flagged subleasing or other actions as necessary to mitigate this ongoing cash operating burden as the footprint is optimized.
Biosecurity Revenue Loss Adds Near-Term Drag
Biosecurity contributed $7 million of revenue in Q4 2025 and $37 million for the full year, but that top‑line will disappear from core operations after the divestiture. While Ginkgo will still benefit from a minority interest, the move creates a near‑term revenue headwind and transition risk as the business changes hands.
Visibility Hit as Revenue Guidance Pulled
Executives declined to provide 2026 revenue guidance, opting instead to focus investors on tightening cash burn and investing in autonomous labs. The shift reflects strategic priorities but reduces near‑term visibility on the topline, leaving markets to infer growth from bookings like the $47 million PNNL deal.
Market Weakness and Scaling Friction
Industrial and industrial‑biotech markets remain sluggish, weighing on some of Ginkgo’s legacy demand since 2022. Management also acknowledged that scaling frontier autonomous systems comes with debugging and cultural onboarding challenges, which can slow adoption and create execution friction with early customers.
Manufacturing RACs at Scale
The design of Ginkgo’s RAC units has been improved for manufacturability and current capacity can meet early needs, but management stressed that broader rollouts will demand planning. Future growth will require expanded manufacturing partnerships and tighter execution to match rising customer interest in RAC deployments.
Guidance Centers on Runway and Lab Expansion
Forward‑looking commentary focused on cash preservation and capacity build‑out rather than sales targets, with 2026 cash burn guided to $125 million to $150 million and about $430 million of cash on hand. Ginkgo reiterated its plan to double Boston RAC capacity to roughly 100 units by the first half and to complete the Biosecurity divestiture while leaning into autonomous‑lab investment.
Ginkgo’s earnings call painted a picture of a company aggressively pivoting toward AI‑enabled labs and disciplined spending while still wrestling with revenue declines and continuing losses. For investors, the story now hinges on whether marquee deals, data services and RAC scale‑up can convert technical momentum and cost cuts into durable, profitable growth over the coming years.
